Cue Biopharma, Inc.CUENASDAQ
Loading
EV to Sales: Discounted ValuationCompressed
Percentile Rank30
3Y CAGR-84.2%
5Y CAGR-70.2%
Studio
Year-over-Year Change

Enterprise value to sales ratio

3Y CAGR
-84.2%/yr
vs -3.7%/yr prior
5Y CAGR
-70.2%/yr
Recent deceleration
Acceleration
-80.6pp
Decelerating
Percentile
P30
Within normal range
vs 5Y Ago
0x
Contraction
Streak
3 yr
Consecutive declineCompressed
PeriodValueYoY Change
20250.22-95.8%
20245.15-67.5%
202315.84-71.5%
202255.66+175.9%
202120.18-78.1%
202092.31+2.5%
201990.05+39.4%
201864.62-
20170.00-
20160.00-